CL2016000788A1 - Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016) - Google Patents

Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)

Info

Publication number
CL2016000788A1
CL2016000788A1 CL2016000788A CL2016000788A CL2016000788A1 CL 2016000788 A1 CL2016000788 A1 CL 2016000788A1 CL 2016000788 A CL2016000788 A CL 2016000788A CL 2016000788 A CL2016000788 A CL 2016000788A CL 2016000788 A1 CL2016000788 A1 CL 2016000788A1
Authority
CL
Chile
Prior art keywords
pharmaceutical dosage
atrasentán
divisional
application
dosage forms
Prior art date
Application number
CL2016000788A
Other languages
English (en)
Inventor
Ye Huang
Andrew K Koski
Katherine E Peterson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2016000788A1 publication Critical patent/CL2016000788A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMA DE DOSIFICACIÓN FARMACÉUTICA SÓLIDA ESTABLE QUE COMPRENDE A) ENTRE 0,25 Y 1,25 MG DE ATRASENTÁN O UNA SAL DEL MISMO, B) UN AGLUTINANTE POLIMÉRICO Y C) UN DILUYENTE; Y MÉTODO PARA REDUCIR LA ALBÚMINA A CREATININA URINARIA EN UN SUJETO HUMANO QUE PADECE UNA ENFERMEDAD RENAL CRÓNICA.
CL2016000788A 2013-07-08 2016-04-05 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016) CL2016000788A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361843799P 2013-07-08 2013-07-08

Publications (1)

Publication Number Publication Date
CL2016000788A1 true CL2016000788A1 (es) 2016-11-11

Family

ID=51211921

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000027A CL2016000027A1 (es) 2013-07-08 2016-01-07 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.
CL2016000788A CL2016000788A1 (es) 2013-07-08 2016-04-05 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016000027A CL2016000027A1 (es) 2013-07-08 2016-01-07 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.

Country Status (19)

Country Link
US (2) US9364458B2 (es)
EP (1) EP3019158A1 (es)
JP (1) JP2016530238A (es)
KR (1) KR20160029125A (es)
CN (1) CN105517541A (es)
AU (1) AU2014287496A1 (es)
CA (1) CA2916033C (es)
CL (2) CL2016000027A1 (es)
CR (1) CR20160037A (es)
DO (1) DOP2016000003A (es)
EC (1) ECSP16005195A (es)
HK (1) HK1223825A1 (es)
IL (1) IL243242B (es)
MX (1) MX2016000188A (es)
PE (1) PE20160221A1 (es)
PH (1) PH12016500042A1 (es)
RU (1) RU2016103764A (es)
SG (2) SG10201700596PA (es)
WO (1) WO2015006219A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006219A1 (en) * 2013-07-08 2015-01-15 Abbvie, Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US10929741B2 (en) 2018-06-18 2021-02-23 University Of Florida Research Foundation, Incorporated Cross-registration for unclonable chipless RFID tags
BR112022012075A2 (pt) * 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
CA3188345A1 (en) 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2342217C (en) 1998-09-14 2009-12-15 Abbott Laboratories Process for producing stereoselective nitro compounds
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20060189675A1 (en) * 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
CA2578824A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
KR20110119108A (ko) 2010-04-26 2011-11-02 울산대학교 산학협력단 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
WO2015006219A1 (en) * 2013-07-08 2015-01-15 Abbvie, Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Also Published As

Publication number Publication date
US10016393B2 (en) 2018-07-10
ECSP16005195A (es) 2017-02-24
CR20160037A (es) 2016-04-05
RU2016103764A3 (es) 2018-05-31
CA2916033A1 (en) 2015-01-15
DOP2016000003A (es) 2016-02-15
EP3019158A1 (en) 2016-05-18
CA2916033C (en) 2022-08-23
RU2016103764A (ru) 2017-08-11
KR20160029125A (ko) 2016-03-14
SG11201600107RA (en) 2016-02-26
US20150011602A1 (en) 2015-01-08
IL243242A0 (en) 2016-02-29
CN105517541A (zh) 2016-04-20
IL243242B (en) 2020-11-30
HK1223825A1 (zh) 2017-08-11
SG10201700596PA (en) 2017-02-27
MX2016000188A (es) 2016-03-09
WO2015006219A1 (en) 2015-01-15
CL2016000027A1 (es) 2016-07-22
AU2014287496A1 (en) 2016-01-07
PH12016500042A1 (en) 2016-03-28
US9364458B2 (en) 2016-06-14
US20160250186A1 (en) 2016-09-01
JP2016530238A (ja) 2016-09-29
PE20160221A1 (es) 2016-05-22

Similar Documents

Publication Publication Date Title
CL2016000788A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)
CY1124389T1 (el) Υποκατεστημενα 3-αζαδικυκλο[3.1.0]εξανια ως αναστολεις κετοεξωκινασης
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
CU20170168A7 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
EP4054556A4 (en) SODIUM-GLUCOSE TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY FAILURE, HYPERTENSION AND HEART FAILURE IN PETS
UY35354A (es) Combinaciones que comprenden compuestos maba y corticosteroides
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
UY35677A (es) Combinaciones que comprenden compuestos maba y corticosteroides
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
CL2015001730A1 (es) Compuestos triciclos inhibidores del canal cftr; composicion y combinacion farmaceutica; y uso en el tratamiento de la enfermedad renal poliquistica y diarrea.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
ECSP16060194A (es) Formas de dosificación farmacéuticas
CL2015002951A1 (es) Silicato de zirconio microporoso y diuréticos para la reducción de potasio y el tratamiento de una enfermedad crónica del riñón y/o crónica del corazón.
CL2008002005A1 (es) Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.
ES1138833U (es) Tapón escanciador
AR098028A1 (es) Ácido 4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxiacético para su uso en la prevención o el tratamiento de la lesión renal aguda
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato